EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Small molecules for inflammatory bowel disease and the risk of infection and malignancy: A systematic review and meta-Analysis

LiXue Chen, Chang Su, Hao Ding, Qiao Mei

Digestive and Liver Disease · 2024-11 · 56 (11) · 1828-1838

DOI: 10.1016/j.dld.2024.07.018 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Digestive and Liver Disease, 2024-11. Verfasst von LiXue Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, the First Affiliated Hospital of Anhui Medical University, He Fei 230022, China. Hauptthemen laut MEDLINE: Infections, Inflammatory Bowel Diseases, Janus Kinase Inhibitors, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This meta-analysis aimed to ascertain whether small molecule drugs increase the risk of infection or malignancy in adult IBD patients. METHODS: A comprehensive search of eight databases was conducted from their inception to November 2023. The risk of infections or malignancies in adult IBD patients treated with JAK inhibitors and S1P receptor modulators was compared. Fixed-effects or random-effects models were performed, and relative risk (RR) and 95 % confidence interval (CI) were calculated. RESULTS: 27 RCTs from 14 studies were included (n = 10,623). The evidence indicates that small molecule drugs increase the risk of any infections (RR: 1.23, 95 %CI: 1.05-1.44) and herpes zoster (RR: 2.23, 95 %CI: 1.39-3.57). Specifically, UC patients on Filgotinib and Tofacitinib, and CD patients on Upadacitinib, showed elevated risks of any infections (RR: 1.27, 95 % CI: 1.04-1.56; RR: 1.42, 95 % CI: 1.16-1.75; RR: 1.57, 95 % CI: 1.11-2.22). CD patients on Upadacitinib also had a significantly higher risk of herpes zoster (RR: 2.64, 95 %CI: 1.16-5.99). No infections were associated with S1P receptor modulators, and similarly, no malignancies were linked to small molecule drugs. CONCLUSIONS: JAK inhibitors increase the risk of any infections and herpes zoster Over a one-year follow-up period in IBD patients. Continuous monitoring of their long-term safety is necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfectionsInflammatory Bowel DiseasesJanus Kinase InhibitorsNeoplasmsHumansHerpes ZosterHeterocyclic Compounds, 3-RingPiperidinesPyrimidinesRandomized Controlled Trials as TopicTriazolesPyridines

Stichwörter der Autor:innen

Crohn's diseaseInflammatory bowel diseaseSmall molecule drugsUlcerative colitis

Substanzen

Heterocyclic Compounds, 3-RingJanus Kinase InhibitorsPiperidinesPyrimidinesTriazolesGLPG0634Pyridinestofacitinibupadacitinib

Autor:innen und Institutionen

  • Department of Gastroenterology, the First Affiliated Hospital of Anhui Medical University, He Fei 230022, China.
  • Department of Gastroenterology, the First Affiliated Hospital of Anhui Medical University, He Fei 230022, China. Electronic address: kbcgsagzsl@163.com.

Zitieren

APA

Chen, L., Su, C., Ding, H., & Mei, Q. (2024). Small molecules for inflammatory bowel disease and the risk of infection and malignancy: A systematic review and meta-Analysis. Digestive and Liver Disease, 56(11), 1828-1838. https://doi.org/10.1016/j.dld.2024.07.018

Vancouver

Chen L, Su C, Ding H, Mei Q. Small molecules for inflammatory bowel disease and the risk of infection and malignancy: A systematic review and meta-Analysis. Digestive and Liver Disease. 2024;56(11):1828-1838. doi:10.1016/j.dld.2024.07.018

BibTeX
@article{Chen2024,
  author = {Chen, LiXue and Su, Chang and Ding, Hao and Mei, Qiao},
  title = {Small molecules for inflammatory bowel disease and the risk of infection and malignancy: A systematic review and meta-Analysis},
  journal = {Digestive and Liver Disease},
  year = {2024},
  volume = {56},
  number = {11},
  pages = {1828--1838},
  doi = {10.1016/j.dld.2024.07.018}
}
Kostenlos starten →